PUBLISHER: IMARC | PRODUCT CODE: 1450977
PUBLISHER: IMARC | PRODUCT CODE: 1450977
The global next-generation sequencing (NGS) market size reached US$ 20.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 80.4 Billion by 2032, exhibiting a growth rate (CAGR) of 16.2% during 2024-2032.
Next-generation sequencing (NGS) is a parallel sequencing technology that determines the sequence of nucleotides in a section of the deoxyribonucleic acid (DNA). It involves various procedures, such as sequencing by synthesis (SBS) and ion semiconductor, single-molecule real-time (SMRT), and nanopore sequencing. It is a cost-effective solution that assists medical professionals in achieving precise results with high accuracy and speed. It also facilitates research in the fields of clinical diagnostics, personalized and genetic medicines, and agriculture and animal studies. At present, it is utilized in pharmacogenomics to escalate the drug delivery process.
The growing global geriatric population and the rising prevalence of various chronic medical disorders, such as cancer, cardiovascular, and neurological disorders, represent one of the key factors positively influencing the market. It can also be attributed to the growing use of genetic maps for guiding scientists to analyze the genes that are responsible for medical conditions. In addition, the widespread adoption of liquid biopsies in cancer diagnostics and the increasing utilization of NGS technologies to introduce non-invasive cancer biomarkers for real-time cancer monitoring and detection are creating a positive market outlook. In line with this, continuous technological innovations in sequencers, such as the integration of cloud-computing systems for enhanced data security and management, are strengthening the market growth. Apart from this, continuous financing by governments of various countries to improve healthcare infrastructure is providing a thrust to the market growth. Furthermore, increasing investments by leading players in research and development (R&D) activities for molecular biology, technical engineering, and sequencing chemistry is offering a favorable market outlook.
IMARC Group provides an analysis of the key trends in each segment of the global next-generation sequencing (NGS) market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on sequencing type, product type, technology, application and end-user.
Whole Genome Sequencing
Targeted Resequencing
Whole Exome Sequencing
RNA Sequencing
CHIP Sequencing
De Novo Sequencing
Methyl Sequencing
Others
Targeted resequencing represents the largest market segment due to the presence of numerous companies in the NGS market offering targeted resequencing services.
Instruments
Reagents and Consumables
Software and Services
Reagents and consumables represent the most commonly used product type that assists in sample preparation, DNA isolation, sample cleanup, target enrichment, and quality assurance.
Sequencing by Synthesis
Ion Semiconductor Sequencing
Single-Molecule Real-Time Sequencing
Nanopore Sequencing
Others
Sequencing by synthesis finds extensive applications on account of its high accuracy in performing DNA sequencing and its growing incorporation in NGS instrumentation. In addition, it offers the highest yield of error-free throughput results.
Biomarker and Cancer
Drug Discovery and Personalized Medicine
Genetic Screening
Diagnostics
Agriculture and Animal Research
Others
Biomarker and cancer currently dominate the market due to the rising prevalence of cancer and increasing awareness among individuals about the benefits of early diagnosis and treatment.
Academic Institutes & Research Centers
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Others
Academic institutes and research centers account for the majority of the market share due to the increasing application of NGS solutions in research projects.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market due to the availability of a technologically advanced healthcare research framework in the region, coupled with the presence of multiple clinical laboratories that employ NGS to provide genetic testing services.
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc.